Merck (MRK) Tops Q4 EPS by 9c; Guides FY23 EPS Below the Street

Merck (NYSE: MRK) reported Q4 EPS of $1.62, $0.09 better than the analyst estimate of $1.53. Revenue for the quarter came in at $13.8 billion versus the consensus estimate of $13.65 billion.

GUIDANCE:

Merck sees FY2023 EPS of $6.80-$6.95, versus the consensus of $7.36. Merck sees FY2023 revenue of $57.2-58.7 billion, versus the consensus of $58.07 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c